Metabolomics-Based Clinical Efficacy and Effect on the Endogenous Metabolites of Tangzhiqing Tablet, a Chinese Patent Medicine for Type 2 Diabetes Mellitus with Hypertriglyceridemia
Table 3
The comparison of baseline characteristics between case group and normal group in metabolomics (mean ± SD).
Variable
Normal group (n=5)
Case group (n=10)
TZQ group (n=5)
placebo group (n=5)
mean ± SD
mean ± SD
p
mean±SD
p
Sex (M/F)
2/3
2/3
4/1
Age (year)
60.60±1.95
62.60±6.43
0.524
49.80±8.76
0.027
BMI (kg/m2)
20.82±0.92
24.92±3.80
0.047
29.32±4.37
0.003
Waistline (cm)
73.60±4.72
93.30±16.10
0.031
98.40±7.27
<0.001
HbA1c (%)
4.66±0.92
7.84±0.75
<0.001
7.96±0.71
<0.001
FINS (mIU/L)
9.50±4.29
16.71±8.87
0.140
14.66±5.90
0.153
FBG (mmol/L)
4.66±0.50
6.89±1.30
0.007
8.29±1.34
<0.001
OGTT2hBG (mmol/L)
9.26±0.92
12.38±1.32
0.002
14.42±1.46
<0.001
TG (mmol/L)
1.04±0.06
2.24±0.42
<0.001
2.61±0.47
<0.001
TC (mmol/L)
3.47±0.68
5.29±0.64
0.002
4.88±0.39
0.004
LDL-C (mmol/L)
1.88±0.61
3.06±0.41
0.007
2.88±0.36
0.013
HDL-C (mmol/L)
1.50±0.22
1.21±0.26
0.087
0.95±0.28
0.009
Note: data were analyzed using independent sample t test. FBG: fasting blood glucose; OGTT2hBG: oral glucose tolerance test 2 h blood glucose; HbA1c: glycosylated hemoglobin; BMI: body mass index; TC: total cholesterol; TG: triglyceride; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol.
